Accuray Hosts Symposium on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting
SUNNYVALE, Calif., July 20, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, will host a symposium examining best practices for quality assurance in radiation oncology at the 2011 Joint American Association of Physicists in Medicine (AAPM)/Canadian Organization of Medical Physicists (COMP) Meeting. The symposium—"Best Quality Assurance Programs for Today's Radiation Oncology Platforms"—will discuss how systems' engineering principles can be applied to radiotherapy quality assurance (QA) and quality compliance (QC). The 2011 Joint AAPM/COMP Meeting takes place July 31-August 4, 2011 in Vancouver, British Columbia.
Sonja Dieterich, Ph.D., DABR, Chief of Clinical Physics at Stanford University School of Medicine, and Sasa Mutic, Ph.D., Chief of Clinical Medical Physics and Associate Professor of Radiation Oncology at Washington University School of Medicine
A complimentary luncheon and discussion of best practices for QA in radiation oncology. The symposium will also discuss the protocols and recommendations of task group TG-135, which has been dedicated to setting QA standards in the field of robotic radiosurgery.
Monday, August 1, 2011
12:30 PM to 2:00 PM PDT
The 2011 Joint AAPM/COMP Meeting
Fairmont Pacific Rim
1038 Canada Place
Vancouver, British Columbia
Precision radiosurgery and intensity-modulated radiotherapy require strict QA to ensure safe operation. This symposium will highlight QC measurements and QA procedures that can minimize adverse results related to Accuray's technologies including the CyberKnife® Robotic Radiosurgery System and the TomoTherapy® Radiation Therapy System.
Attendees interested in participating in the symposium may register online.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company. Accuray develops, manufactures and sells personalized, best-in-class treatment solutions that revolve around the patient. Accuray's game-changing technologies – the CyberKnife System and TomoTherapy System – set the standard of care with the aim of helping patients live longer, better lives. To date, more than 200,000 patients worldwide have been treated using the company's technologies and more than 550 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D.
SOURCE Accuray Incorporated